Leslie Sloan - AGLE Old Chief Officer
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
Executive
Dr. Leslie Sloan is Chief Operating Officer of the Company. Dr. Sloan has served as Aegleas Vice President of Operations since August 2017. Prior to joining Aeglea, between March 2012 and April 2017, Dr. Sloan served in various roles of increasing responsibility at Ipsen Bioscience Inc., a biopharmaceutical company, including as Senior Director Head of RD Operational Excellence, Vice President, RD Project Management Analytics, leading the strategic and operational execution of its global RD portfolio, and President of Ipsen Bioscience Inc. Prior to that, she also served as Senior Director at Pfizer, where she was a member of the RD clinical candidate survival council and candidate quality guidelines committee since 2019.
| Age | 52 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Phone | 512 942 2935 |
| Web | https://www.aeglea.com |
AGLE Old Management Efficiency
The company has return on total asset (ROA) of (0.4182) % which means that it has lost $0.4182 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8141) %, meaning that it created substantial loss on money invested by shareholders. AGLE Old's management efficiency ratios could be used to measure how well AGLE Old manages its routine affairs as well as how well it operates its assets and liabilities.AGLE Old currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. AGLE Old has a current ratio of 4.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about AGLE Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bob Lally | Ikena Oncology | N/A | |
| MBA MBA | Bio Path Holdings | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Matthew MD | Cingulate | 60 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
| Katarina MD | Xilio Development | 48 | |
| Robert MBBS | Instil Bio | N/A | |
| Marc MD | Edgewise Therapeutics | 67 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
| Scott Coleman | Xilio Development | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| MD FACC | Design Therapeutics | 55 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Claudia Kloth | Benitec Biopharma Ltd | N/A | |
| Colleen Sjogren | Nuvation Bio | 54 | |
| Chau MBA | CytomX Therapeutics | N/A | |
| Charles Garner | Aileron Therapeutics | 48 | |
| MD MBA | Eliem Therapeutics | 50 | |
Management Performance
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 |
AGLE Old Leadership Team
Elected by the shareholders, the AGLE Old's board of directors comprises two types of representatives: AGLE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AGLE. The board's role is to monitor AGLE Old's management team and ensure that shareholders' interests are well served. AGLE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AGLE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James JD, Pres CEO | ||
| Jonathan MBA, CFO Officer | ||
| Michael MBA, Chief Officer | ||
| Josie Gayton, Operations Strategy | ||
| Cortney MBA, VP Operations | ||
| Leslie Sloan, Chief Officer | ||
| Kelly Boothe, Sr Relations | ||
| Jeffrey Goldberg, CEO Pres | ||
| Joey Perrone, Director- Finance, IR Contact Officer | ||
| Scott Rowlinson, Vice President - Research | ||
| MBA MD, Chief Officer |
AGLE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AGLE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (94.85) % | |||
| Current Valuation | 228.21 M | |||
| Shares Outstanding | 4.05 M | |||
| Shares Owned By Insiders | 2.40 % | |||
| Shares Owned By Institutions | 97.60 % | |||
| Number Of Shares Shorted | 128.62 K | |||
| Price To Earning | (2.41) X | |||
| Price To Book | 0.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in AGLE Stock
If you are still planning to invest in AGLE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AGLE Old's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |